article thumbnail

MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation

Cannabis Law Report

Studies estimate that the number of people suffering from rheumatoid arthritis may rise to over 78 million by 2040. a driver of chronic inflammation. Unlike other therapies, MYMD-1 has been shown to selectively block TNF-? No approved TNF inhibitor has ever been dosed orally.